Akebia Therapeutics, Inc. (AKBA) Financial Statements
Akebia Therapeutics, Inc. (AKBA) reported trailing twelve-month revenue of $219.1M (up 7.5% year on year) and net income of -$29.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $40.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AKBAAkebia Therapeutics, Inc.Follow AKBA — free
—
Price chart with a free account
- Market cap
- 157.1M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 207.7 | 335.0 | 294.6 | 211.7 | 292.5 | 194.6 | 160.2 | 236.2 | 219.1 | |
| Gross profit | 200.0 | 189.7 | -1.8 | 61.0 | 206.9 | 120.5 | 97.0 | 196.7 | 174.4 | |
| Research & development | 291.0 | 323.0 | 218.5 | 147.9 | 130.0 | 63.1 | 37.7 | 62.4 | 70.5 | |
| Operating income | -178.2 | -286.3 | -377.8 | -264.5 | -80.8 | -46.3 | -50.5 | 23.5 | -15.1 | |
| Pre-tax income | -171.9 | -286.3 | -384.8 | -282.0 | -94.2 | -51.9 | -69.4 | -3.7 | -27.8 | |
| Income tax | -28.3 | -6.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 1.8 | |
| Net income | -143.6 | -279.7 | -384.8 | -282.0 | -94.2 | -51.9 | -69.4 | -5.3 | -29.7 | |
| Diluted EPS ($) | -2.47 | -2.36 | -2.77 | -1.70 | -0.52 | -0.28 | -0.33 | -0.02 | -0.11 | |
| Diluted shares (mn) | — | — | — | 165.9 | 182.8 | 187.5 | 210.9 | 257.2 | — |
USD millions · SEC XBRL
Akebia Therapeutics, Inc. — questions
- What is Akebia Therapeutics, Inc.'s revenue?
- $219.1M over the twelve months to 2026-06-30, up 7.5% year on year, from its 10-Q and 10-K filings.
- What is Akebia Therapeutics, Inc.'s net income?
- -$29.7M over the twelve months to 2026-06-30.
- What is Akebia Therapeutics, Inc.'s free cash flow?
- $40.3M over the twelve months to 2026-06-30.
- What are Akebia Therapeutics, Inc.'s diluted earnings per share?
- $-0.11 over the twelve months to 2026-06-30.
Every figure on this page comes from Akebia Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.